Related references
Note: Only part of the references are listed.Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias
D. Frappaz et al.
SUPPORTIVE CARE IN CANCER (2021)
MEVITEM-a phase I/II trial of vismodegib plus temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation
Didier Frappaz et al.
NEURO-ONCOLOGY (2021)
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2020)
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
O. Tredan et al.
ANNALS OF ONCOLOGY (2019)
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Paul Lesueur et al.
BMC CANCER (2019)
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskil Eskilsson et al.
NEURO-ONCOLOGY (2018)
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match ((NM2)-M-2) pilot study
Elke Pfaff et al.
NEURO-ONCOLOGY (2018)
Relapse pathway of glioblastoma revealed by single-cell molecular analysis
Xuelian Chen et al.
CARCINOGENESIS (2018)
Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study
Patricia Marino et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2018)
Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages
Sathishkumar Baskaran et al.
NEURO-ONCOLOGY (2018)
Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma
Takuya Furuta et al.
NEUROPATHOLOGY (2018)
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients
Javier M. Figueroa et al.
NEURO-ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation
Nuala A. O'Leary et al.
NUCLEIC ACIDS RESEARCH (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Adolescent and Young Adults (AYAS) brain tumor national Web conference. On behalf of ANOCEF, GO-AJA and SFCE societies
Didier Frappaz et al.
BULLETIN DU CANCER (2016)
Glioblastoma: pathology, molecular mechanisms and markers
Kenneth Aldape et al.
ACTA NEUROPATHOLOGICA (2015)
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W. Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers
Janessa Laskin et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2015)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies
Akio Iwanami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
PHASE II EVALUATION OF GEFITINIB IN PATIENTS WITH NEWLY DIAGNOSED GRADE 4 ASTROCYTOMA: MAYO/NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0074
Joon H. Uhm et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
The real cost of sequencing: higher than you think!
Andrea Sboner et al.
GENOME BIOLOGY (2011)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W. K. Alfred Yung et al.
NEURO-ONCOLOGY (2010)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway
Rafael Rosell et al.
CLINICAL CANCER RESEARCH (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
dbSNP: the NCBI database of genetic variation
ST Sherry et al.
NUCLEIC ACIDS RESEARCH (2001)